BioCentury
ARTICLE | Product Development

‘Diversified’ gut-brain axis company Kallyope heading to clinic with $112M series C

Kallyope chooses obesity, IBD for its first two gut-restricted small molecule programs

March 25, 2020 7:45 PM UTC
Updated on Mar 27, 2020 at 7:45 PM UTC

With what CEO Nancy Thornberry described as a breadth of options spanning multiple therapeutic areas, gut-brain axis company Kallyope will use its new $112 million series C round to bring its first two small molecule programs into the clinic to treat obesity and inflammatory bowel disease.

All of Kallyope Inc.’s series B investors backed the new round: The Column Group, Lux Capital, Polaris Partners, Euclidean Capital, Two Sigma Ventures, Illumina Ventures, Alexandria Venture Investments and Bill Gates. New investors included Casdin Capital, Greenspring Associates and two undisclosed firms...

BCIQ Company Profiles

Kallyope Inc.